Tag Archives: teva

Teva’s Auspex Buyout Pays, But Mylan Bid Hits Snag

Israeli drug giant Teva Pharmaceutical Industries (TEVA) reported positive results for a recently acquired drug Tuesday. Teva stock was down a fraction, however, as the company also faced a new roadblock in its effort to take over Mylan (MYL). Teva said that SD-809, a drug that it had gained in its $3.5 billion buyout of Auspex Pharmaceuticals last month, hit the primary endpoint in a pivotal trial of tardive dyskinesia, a movement disorder that

IPO Stock Watch: Alder Soars On Migraine Drug Results

Small biotech and year-old new issue Alder BioPharmaceuticals (ALDR) soared more than 12% to a new high near 40 on Friday after it presented positive clinical-trial data on its migraine drug candidate, presenting a challenge to such larger players as Amgen (AMGN), Eli Lilly (LLY) and Teva Pharmaceutical (TEVA). Alder said that a single intravenous injection of its drug candidate ALD403 was still working in patients six months later, with 61%

Teva, Celgene, Novo Nordisk, Shire Report Q1 Earnings

Four big-cap drugmakers reported mostly solid first quarters Thursday morning, but the market gave them a decidedly mixed reception. Israeli generic-drug giant Teva Pharmaceutical (TEVA) reported earnings minus one-time items of $1.36 a share, up 11.5% from the year-earlier quarter and beating analyst consensus by 11 cents, according to Thomson Reuters. Sales declined a fraction to $4.98 billion, but beat Street estimates by $150 million.